HPR50 Life-YEARS Gained with Conditional Reimbursement Access to Innovative Oncological and Hematological Medicines in Finland
Jul 1, 2022, 00:00 AM
10.1016/j.jval.2022.04.976
https://www.valueinhealthjournal.com/article/S1098-3015(22)01177-9/fulltext
Section Title :
Section Order :
10881
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)01177-9&doi=10.1016/j.jval.2022.04.976